The Application of Nanobody in CAR-T Therapy

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Feb 11

PMID 33567640

Citations 39

Authors

Chaolemeng Bao

Quanli Gao

Lin-Lin Li

Lu Han

Bingxiang Zhang

Yijin Ding

Zongpei Song

Ruining Zhang

Jishuai Zhang

Xian-Hui Wu

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks.

Citing Articles

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.

Guo S, Xi X Biomark Res. 2025; 13(1):41.

PMID: 40069884 PMC: 11899093. DOI: 10.1186/s40364-025-00755-5.

Targeting BCMA in multiple myeloma: designs, challenges, and future directions.

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z Cancer Immunol Immunother. 2025; 74(3):77.

PMID: 39891674 PMC: 11787132. DOI: 10.1007/s00262-024-03913-0.

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.

Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y Front Immunol. 2025; 15:1476859.

PMID: 39749335 PMC: 11694027. DOI: 10.3389/fimmu.2024.1476859.

The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.

Yao P, Liu Y, Huang G, Hao L, Wang R Exp Hematol Oncol. 2024; 13(1):118.

PMID: 39633491 PMC: 11616395. DOI: 10.1186/s40164-024-00583-7.

Distinct types of VHHs in Alpaca.

Wang X, Zhang L, Zhang Y, Li J, Xu W, Zhu W Front Immunol. 2024; 15:1447212.

PMID: 39600702 PMC: 11588638. DOI: 10.3389/fimmu.2024.1447212.

References

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I . Revisiting Interleukin-12 as a Cancer Immunotherapy Agent. Clin Cancer Res. 2018; 24(12):2716-2718. DOI: 10.1158/1078-0432.CCR-18-0381. View

Eshhar Z, Waks T, Gross G . The emergence of T-bodies/CAR T cells. Cancer J. 2014; 20(2):123-6. DOI: 10.1097/PPO.0000000000000027. View

Zhao W, Liu J, Wang B, Chen Y, Cao X, Yang Y . A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018; 11(1):141. PMC: 6302465. DOI: 10.1186/s13045-018-0681-6. View

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Nguyen K, Vrabel M, Mantooth S, Hopkins J, Wagner E, Gabaldon T . Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020; 11:575597. PMC: 7593768. DOI: 10.3389/fimmu.2020.575597. View

Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X . Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol. 2019; 203(1):198-207. DOI: 10.4049/jimmunol.1800033. View

Hong M, Clubb J, Chen Y . Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020; 38(4):473-488. DOI: 10.1016/j.ccell.2020.07.005. View

Kowolik C, Topp M, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N . CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006; 66(22):10995-1004. DOI: 10.1158/0008-5472.CAN-06-0160. View

10.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

11.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

12.

Yanez L, Sanchez-Escamilla M, Perales M . CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere. 2019; 3(2):e186. PMC: 6746032. DOI: 10.1097/HS9.0000000000000186. View

13.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S . Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016; 126(8):3036-52. PMC: 4966331. DOI: 10.1172/JCI83416. View

14.

Rahbarizadeh F, Rasaee M, Forouzandeh Moghadam M, Allameh A, Sadroddiny E . Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid Hybridomics. 2004; 23(3):151-9. DOI: 10.1089/1536859041224334. View

15.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K . Nanobody Based Dual Specific CARs. Int J Mol Sci. 2018; 19(2). PMC: 5855625. DOI: 10.3390/ijms19020403. View

16.

Carlotti F, Zaldumbide A, Martin P, Boulukos K, Hoeben R, Pognonec P . Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther. 2005; 12(7):627-39. DOI: 10.1038/sj.cgt.7700825. View

17.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View

18.

Khan K, Kerbel R . Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018; 15(5):310-324. DOI: 10.1038/nrclinonc.2018.9. View

19.

Chen W, Zhu Z, Xiao X, Dimitrov D . Construction of a human antibody domain (VH) library. Methods Mol Biol. 2009; 525:81-99, xiii. PMC: 2801874. DOI: 10.1007/978-1-59745-554-1_4. View

20.

Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein A, Ortolan E . Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88(3):841-86. DOI: 10.1152/physrev.00035.2007. View